Artivion (AORT) AI Stock Analysis

• Market Cap: $1.23B
• Dividend Yield: N/A
• Average Volume (3M): 537.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: 5.94%
• EPS Growth: -115.82%
• Country: US
• Employees: 1,600
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 42,702,785
• 10 Day Avg. Volume: 708,797
• 30 Day Avg. Volume: 537,212
• PEG Ratio: 0.94
• Price to Book (P/B): 4.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 573.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $32.50
• Price Target Upside: 12.15% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Artivion's stock reflects a mix of solid revenue growth and profitability challenges. The earnings call provided a positive outlook with raised guidance and strong product performance, offsetting cybersecurity and regional revenue issues. Technical indicators show strong momentum, but valuation concerns remain due to negative earnings.

Positive Factors

Financial Performance

AORT's 1Q25 revenue and EBITDA beat consensus.

Market Expansion

The earlier-than-expected approval of the AMDS humanitarian-device-exemption is anticipated to positively contribute to 2025 top-line growth.

Product Launch

The AMDS launch is progressing well with approximately 150 centers seeking approvals.

Negative Factors

Cybersecurity Impact

A cybersecurity incident impacted Q4 revenue by $4.5M due to inventory constraints, causing revenue to fall below expectations.

Price Target

The price target was lowered to $32 from $34, given the cybersecurity issue.

Revenue Impact

Q1 is expected to continue feeling the impact of the cybersecurity incident, affecting revenue recognition.

Artivion Business Overview & Revenue Model

Company Description

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

How the Company Makes Money

Artivion generates revenue primarily through the sale of its medical devices, particularly in the areas of heart valves and surgical grafts used in cardiac surgeries. The company sells its products to hospitals and healthcare providers, both directly and through distribution partners, enabling them to reach a broad customer base. Additionally, Artivion invests in research and development to continuously innovate and expand its product offerings, which can lead to increased sales and market share. Strategic partnerships and collaborations with research institutions and other industry players also contribute to its revenue by enhancing its product pipeline and market reach.

Artivion Financial Statement Overview

Summary

Artivion shows steady revenue growth in the medical devices sector but struggles with profitability due to consistent net losses and negative net profit margins. The balance sheet reflects a stable equity base and manageable leverage, but cash flow management is hindered by high capital expenditures.

Income Statement

Artivion's income statement shows a modest revenue growth trend over the years, with TTM (Trailing-Twelve-Months) revenue at $390 million, representing a steady increase from previous years. However, the company has been consistently generating net losses, with a TTM net income of -$21.4 million. Gross profit margin remains strong at 62.9% TTM, but the negative net profit margin of -5.5% and declining EBIT margin to 4.5% TTM indicate profitability challenges.

Balance Sheet

The balance sheet reflects a stable equity base with stockholders' equity at $294 million TTM, but a high debt-to-equity ratio of 0.03 in TTM suggests manageable leverage. The equity ratio is a solid 37.2%, indicating a balanced capital structure. Despite these strengths, the negative net income affects return on equity, which remains negative.

Cash Flow

Artivion's cash flow statement indicates a mixed performance. While operating cash flow is positive at $13.6 million TTM, free cash flow growth is weak due to high capital expenditures, resulting in a modest free cash flow of $2.1 million TTM. The operating cash flow to net income ratio is positive, showing some operational efficiency despite net losses.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
390.08M	388.54M	354.00M	313.79M	298.84M	253.23M
	Gross Profit
245.46M	248.78M	229.18M	202.52M	197.51M	167.78M
	EBIT
17.46M	38.87M	5.74M	3.24M	-13.86M	2.44M
	EBITDA
29.03M	51.06M	26.87M	19.73M	25.04M	20.24M
	Net Income Common Stockholders
-21.39M	-13.36M	-30.69M	-19.19M	-14.83M	-16.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
56.55M	53.46M	58.94M	39.35M	55.01M	61.96M
	Total Assets
794.83M	789.10M	792.40M	762.80M	793.05M	789.40M
	Total Debt
351.22M	362.26M	358.34M	356.83M	362.04M	317.37M
	Net Debt
294.67M	308.80M	299.40M	317.48M	307.03M	255.42M
	Total Liabilities
497.50M	512.90M	510.62M	478.47M	492.32M	460.69M
	Stockholders Equity
297.33M	276.20M	281.78M	284.33M	300.73M	328.71M
Cash Flow		Free Cash Flow
2.11M	11.05M	11.39M	-15.87M	-15.68M	5.04M
	Operating Cash Flow
13.61M	22.24M	18.82M	-5.15M	-2.58M	12.37M
	Investing Cash Flow
-47.04M	-28.19M	-502.00K	-10.71M	5.66M	-73.13M
	Financing Cash Flow
14.45M	2.20M	865.00K	-1.64M	-12.22M	93.61M

Artivion Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AORT, the sentiment is Positive. The current price of 28.98 is above the 20-day moving average (MA) of 25.25, above the 50-day MA of 24.51, and above the 200-day MA of 26.80, indicating a bullish trend. The MACD of 1.30 indicates Negative momentum. The RSI at 76.98 is Negative, neither overbought nor oversold. The STOCH value of 90.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AORT.

Artivion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AORT	67 Neutral	$1.23B	―	-7.25%	―	5.94%	-115.82%
KIDS	63 Neutral	$576.38M	―	-11.33%	―	31.28%	-81.86%
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%
AXGN	52 Neutral	$495.52M	―	-7.22%	―	18.81%	67.41%
TNDM	49 Neutral	$1.54B	―	-92.31%	―	27.65%	-28.22%
OFIX	47 Neutral	$489.37M	―	-27.82%	―	5.85%	-8.92%
BVS	47 Neutral	$553.65M	―	-19.79%	―	8.60%	-42.76%

Artivion Corporate Events

Artivion Announces Convertible Notes Exchange Agreement

On May 14, 2025, Artivion, Inc. announced that it entered into privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due July 1, 2025. The agreements involve exchanging approximately $94.54 million in principal amount of these notes for shares of the company’s common stock, with the number of shares determined by the stock’s average trading price over a specified period. The transaction is expected to close around May 28, 2025, and will leave approximately $5.46 million of the notes outstanding. This strategic move is anticipated to impact Artivion’s financial structure and market positioning, potentially affecting stakeholders by altering the company’s debt and equity composition.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Spark’s Take on AORT Stock

According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.

Artivion’s stock reflects a mix of solid revenue growth and profitability challenges. The earnings call provided a positive outlook with raised guidance and strong product performance, offsetting cybersecurity and regional revenue issues. Technical indicators show strong momentum, but valuation concerns remain due to negative earnings.

To see Spark’s full report on AORT stock, click here.